down arrow

Immix Biopharma, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US45258H1068
USD
5.56
0.72 (14.88%)

Dec 05

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

4.755.57

52 Week

1.345.57
Valuation
Technical
Day's Volume

CASH

1.11 M

Shareholding (Mar 2025)

FII

1.59%

Held by 5 FIIs

DII

95.06%

Held by 4 DIIs

Promoter

0.00%

How big is Immix Biopharma, Inc.?

22-Jun-2025

As of Jun 18, Immix Biopharma, Inc. has a market capitalization of 63.56 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -20.91 million over the last four quarters. The company reported shareholder's funds of 13.25 million and total assets of 22.95 million as of Dec 24.

Market Cap: As of Jun 18, Immix Biopharma, Inc. has a market capitalization of 63.56 million, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Immix Biopharma, Inc. reported net sales of 0.00 million and a net profit of -20.91 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 13.25 million and total assets of 22.95 million.

Read More

What does Immix Biopharma, Inc. do?

22-Jun-2025

Immix Biopharma, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $5 million and a market cap of $63.56 million. Key metrics include a negative P/E ratio, no dividend yield, and a return on equity of -217.96%.

Overview: <BR>Immix Biopharma, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -5 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 63.56 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.65 <BR>Return on Equity: -217.96% <BR>Price to Book: 6.63<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Immix Biopharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Immix Biopharma, Inc. shows a neutral technical trend with mixed indicators, underperforming the S&P 500 recently but slightly outperforming it over the past year.

As of 12 September 2025, the technical trend for Immix Biopharma, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with a mix of indicators reflecting varying strengths. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish. However, Bollinger Bands and KST are bearish on both weekly and monthly time frames, and the Dow Theory and OBV are also mildly bearish. The daily moving averages indicate a mildly bullish stance. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -5.86% and -9.13%, respectively, compared to the S&P 500's gains of 1.05% and 2.33%. Over the past year, the stock has slightly outperformed the S&P 500, returning 17.42% versus 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 63 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-2.49

stock-summary
Return on Equity

-497.02%

stock-summary
Price to Book

13.45

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-7 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
158.6%
0%
158.6%
6 Months
153.88%
0%
153.88%
1 Year
120.63%
0%
120.63%
2 Years
7.34%
0%
7.34%
3 Years
375.21%
0%
375.21%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Immix Biopharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Immix Biopharma, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Immix Biopharma, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with a mix of indicators reflecting varying strengths. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish. However, Bollinger Bands and KST are bearish on both weekly and monthly time frames, and the Dow Theory and OBV are also mildly bearish. The daily moving averages indicate a mildly bullish stance. In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -5.86% and -9.13%, respectively, compared to the S&P 500's gains of 1.05% and 2.33%. Over the past year, the stock has slightly outperformed the S&P 500, returning 17.42% versus 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
-40.27%
EBIT to Interest (avg)
-20.50
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.65
Sales to Capital Employed (avg)
0
Tax Ratio
0.20%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
18.68%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.89
EV to EBIT
-2.31
EV to EBITDA
-2.32
EV to Capital Employed
-8.02
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-217.96%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (3.36%)

Foreign Institutions

Held by 5 Foreign Institutions (1.59%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -50.00% vs -22.22% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.60",
          "val2": "-4.70",
          "chgp": "-40.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.60",
          "val2": "-4.40",
          "chgp": "-50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -39.10% vs -90.24% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.50",
          "val2": "-16.10",
          "chgp": "-39.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.70",
          "val2": "-15.60",
          "chgp": "-39.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.60
-4.70
-40.43%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-6.60
-4.40
-50.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -50.00% vs -22.22% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-22.50
-16.10
-39.75%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-21.70
-15.60
-39.10%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -39.10% vs -90.24% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Immix Biopharma, Inc. stock-summary
stock-summary
Immix Biopharma, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."